Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Innate Pharma
  6. News
  7. Summary
    IPH   FR0010331421

INNATE PHARMA

(IPH)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Innate Pharma : Outcome of Innate Pharma's Annual General Meeting

05/28/2021 | 04:07pm EDT

Innate Pharma SA (Euronext Paris: IPH - ISIN: FR0010331421; Nasdaq: IPHA) ('Innate' or the 'Company') announced the voting results of its shareholders at the Annual General Meeting ('AGM'), which took place on May 28, 2021, in Marseille, France without the physical presence of its shareholders. All resolutions were voted on in accordance with the Executive Board's recommendations.

A total of 178 votes were cast out of a total of 31,717,812 shares giving right to 32,180,682 voting rights, representing a quorum of 40.141%.

During the meeting, all seven members of the Supervisory Board who were up for election were re-elected. Pascale Boissel's mandate lasts until the AGM in 2022 and Novo Nordisk A/S, represented by Marcus Schindler, M.D., decided not to seek re-election due to Dr. Schindler's new role as Chief Scientific Officer of Novo Nordisk A/S. Novo Nordisk A/S remains a shareholder in the Company but no longer has a seat on its Supervisory Board.

'Novo Nordisk A/S has been a long-standing member of Innate's Supervisory Board, and we thank them for their valued contributions to the Company,' said Hervé Brailly, Ph.D., Chairman of the Supervisory Board. 'We wish Dr. Schindler much success in his new role and appreciate his support of Innate.'

The AGM recording, the resolutions, the results of the votes and other documents relating to the AGM are available in the Annual General Meeting 2021 section of the Company's website: https://investors.innate-pharma.com/regulated-information/general-shareholders-meeting


***
The Company's 2020 20-F is available on the Investors section of the website.
***

Disclaimer

Innate Pharma SA published this content on 28 May 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 May 2021 20:06:03 UTC.


ę Publicnow 2021
All news about INNATE PHARMA
07/16INNATE PHARMA : Corporate Presentation | July 2021
PU
07/06GLOBAL MARKETS LIVE : Facebook, AngloGold, Didi, Weibo, Daimler...
07/06INNATE PHARMA : Update on Avdoralimab Phase 2 Force Trial in COVID-19 Patients W..
PU
07/06INNATE PHARMA S A : Trial of Avdoralimab for COVID-19 Did Not Meet Goals; To Sto..
MT
07/06INNATE PHARMA : to Stop Evaluating Antibody for COVID-19 After Mid-Stage Failure
MT
07/06Update on Avdoralimab Phase 2 Force Trial in COVID-19 Patients With Severe Pn..
GL
07/06Innate Pharma SA Announces Update on Avdoralimab Phase 2 Force Trial in COVID..
CI
07/01INNATE PHARMA : Monthly statement on outstanding equity shares and voting rights
CO
06/22RESULTS PRESENTED AT 16TH INTERNATIO : 00 p.m. CEST / 8:00 a.m. EDT (Form 6-K)
PU
06/22INNATE PHARMA : presents preliminary data from TELLOMAK trial showing clinical r..
GL
More news
Financials
Sales 2021 40,8 M 48,2 M 48,2 M
Net income 2021 -45,8 M -54,2 M -54,2 M
Net cash 2021 27,8 M 32,9 M 32,9 M
P/E ratio 2021 -2,59x
Yield 2021 -
Capitalization 224 M 266 M 266 M
EV / Sales 2021 4,83x
EV / Sales 2022 2,86x
Nbr of Employees 244
Free-Float 75,2%
Chart INNATE PHARMA
Duration : Period :
Innate Pharma Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INNATE PHARMA
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Last Close Price 2,84 €
Average target price 5,73 €
Spread / Average Target 102%
EPS Revisions
Managers and Directors
Mondher Mahjoubi Chairman-Executive Board & Chief Executive Officer
Frederic Lombard Chief Financial Officer
HervÚ Eloi Dominique Brailly Chairman-Supervisory Board
Eric Vivier Chief Scientific Officer & Senior Vice President
Odile Belzunce Senior VP-Compliance, IT & Operations
Sector and Competitors
1st jan.Capi. (M$)
INNATE PHARMA-17.97%266
MODERNA, INC.269.97%155 195
LONZA GROUP AG26.48%59 070
IQVIA HOLDINGS INC.39.45%47 899
CELLTRION, INC.-24.93%31 463
SEAGEN INC.-6.81%28 780